36 results on '"Broto J"'
Search Results
2. Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies
3. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts
4. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆
5. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
6. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
7. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group
8. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study
9. Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]
10. 1725MO IMMUNOSARC II master trial (phase II of sunitinib and nivolumab): Results from the clear cell sarcoma (CCS) cohort: A GEIS, ISG, and UCL study
11. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study
12. 1932P First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma
13. 1926P Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study
14. 1922P Immunosarc II master trial: phase II of sunitinib and nivolumab in vascular sarcomas cohort - A GEIS, ISG and UCL study
15. 303 (PB083) - ISG15 as a prognostic biomarker in solitary fibrous tumour
16. 475P Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update
17. 1536P Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups
18. 1520O REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
19. 1624MO Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS)
20. 1701P - Inhibition of mTOR signaling enhances trabectedin activity in soft tissue sarcoma
21. 1674PD - Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups
22. 1669O - IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: Results of the phase II- soft-tissue sarcoma cohort
23. 1659P - Combination of eribulin plus gemcitabine in L-sarcomas
24. 1626P - Trabectedin and radiotherapy in advanced sarcoma: Experience of a reference center
25. LBA55 - Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial
26. 1512P - Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (≥ 5 years) to frontline imatinib (IM): A case-control study from GEIS
27. 1505P - Analysis of expression of immunomodulation factors in alveolar soft-part sarcoma: a retrospective study from the Spanish Group for Research on Sarcoma (GEIS)
28. 1484PD - A matching-adjusted indirect comparison of trabectedin and pazopanib for the treatment of advanced, metastatic, leiomyosarcomas
29. LBA6_PR - sarcoma Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial
30. 1422TiP - Phase II, singlearm, nonrandomized, and multicenter clinical trial of regorafenib (REG) as a single agent in the firstline setting for patients with metastatic and/or unresectable KIT/PDGFR wild-type GIST. A GEIS and ISG study
31. LBA46 - Phase 2 Trial to Evaluate the Efficacy and Safety of Dovitinib in Patients (Pts) with Gastrointestinal Stromal Tumor (Gist) Refractory and/or Intolerant to Imatinib (Im)
32. 1453P - Solitary Fibrous Tumor (Sft): a Registry Program to Assess Frequency and Managemente in Our Country. a Spanish Group for Research on Sarcoma (Geis) Study
33. 1416PD - Integrating Genotype in Risk Classification for Gist Recurrence. a Spanish Group for Sarcoma Research (Geis) Study
34. 1452P - Multidisciplinary Treatment Outcome of Desmoid-Type Fibromatosis (Dtf). a Registry-Based Study from Spanish Group for Research on Sarcoma (Geis)
35. 227P - Prognosis of Phosphorylated-Insulin Growth Factor Receptor (P-Igf-1R) and Metalloproteinase-3 (Mmp3) Expression in Advanced Gastrointestinal Stromal Tumors (Gist) Patients Treated with Imatinib. a Geis Study
36. Intravenous vinorelbine (i.v.VRL) and estramustine (EMP) in patients (pts) with androgen-independent prostate cancer (AIPC): final results
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.